Hypertension and Cardiac Complications

Clinical Presentation and Pathophysiology

The American College of Cardiology notes that hypertension is the most common cardiovascular risk factor underlying atrial fibrillation, present in up to 88% of patients with heart failure and contributing to approximately 24% of incident atrial fibrillation cases 1, 2
The European Society of Cardiology states that chronic hypertension causes left ventricular hypertrophy, left atrial enlargement, diastolic dysfunction, and impaired ventricular filling, creating the substrate for atrial fibrillation through slowed atrial conduction velocity and heterogeneous electrical remodeling 1, 3
The American Heart Association reports that right ventricular hypertrophy develops secondarily when left ventricular diastolic dysfunction progresses, leading to elevated left atrial pressures, which transmit backward to the pulmonary circulation, causing pulmonary hypertension 4
The European Society of Cardiology recommends that patients with hypertension and atrial fibrillation be evaluated for left ventricular hypertrophy and diastolic dysfunction, as these conditions increase the risk of stroke and heart failure 1, 5

The American College of Cardiology guidelines suggest that rheumatic fever would typically present with valvular abnormalities, particularly mitral stenosis, and would have a history of childhood illness, making it less likely in this case 6, 7
The European Society of Cardiology notes that atherosclerosis primarily causes coronary artery disease and would more likely present with ischemic symptoms, myocardial infarction, or left ventricular systolic dysfunction rather than isolated right ventricular hypertrophy 8
The American Heart Association states that genetic predisposition, such as hypertrophic cardiomyopathy, would show marked left ventricular wall thickness and typically presents earlier in life, making it less likely in this case 9

The European Society of Cardiology describes the progression of hypertensive heart disease as follows: chronic hypertension → left ventricular hypertrophy and diastolic dysfunction → elevated left atrial pressure → left atrial enlargement and remodeling → atrial substrate changes → development of atrial fibrillation → backward transmission of pressure → pulmonary hypertension → chronic pulmonary pressure overload → right ventricular hypertrophy and right axis deviation 1, 3, 4, 5
The American College of Cardiology warns that overlooking the sequential nature of right ventricular hypertrophy in the context of hypertension can lead to underestimation of the disease's severity and neglect of comprehensive risk stratification and anticoagulation consideration 4

The European Heart Rhythm Association and ESC Council on Hypertension emphasize that both supraventricular and ventricular arrhythmias occur in hypertensive patients, especially those with left ventricular hypertrophy (LVH), coronary artery disease, or heart failure 10
Hypertension causes both supraventricular and ventricular arrhythmias, with atrial fibrillation being the most common manifestation in patients with chronic hypertensive disease 10

For ventricular arrhythmias, left ventricular hypertrophy is the major determinant of both ventricular arrhythmias and sudden cardiac death in hypertensive patients 11
Activation of the renin-angiotensin-aldosterone system (RAAS) promotes atrial fibrosis via AT1 receptors by increasing TGF-beta1 synthesis, creating disruption of myocardial cell bundles and heterogeneity in intra-atrial conduction 11

Patients with hypertension-induced LVH have greater QTc dispersion, particularly in the context of hypokalemia, creating a substrate similar to long QT syndrome with proarrhythmic potential 12
Prolongation and dispersion of repolarization is a key feature of the pro-arrhythmogenic impact of LVH, with sympathetic activation serving as a trigger for ventricular arrhythmias 11

Effective blood pressure control may prevent the development of arrhythmias such as atrial fibrillation, and achieving adequate BP control with LVH regression is a central management goal 10, 12
ACE inhibitors or ARBs are recommended in hypertensive patients at high risk for sudden cardiac death, as they demonstrate SCD reduction independent of blood pressure reduction 12
Beta-blockers provide additional benefit in patients with concomitant coronary artery disease, though they may be inferior to other antihypertensive classes for LV mass reduction 12

High doses of thiazide diuretics may result in hypokalemia and hypomagnesemia, further contributing to both atrial and ventricular arrhythmias 10, 12
In asymptomatic hypertensive patients with normal LV systolic function and non-sustained ventricular arrhythmias, there is no role for prophylactic antiarrhythmic drugs 12
Class IC agents such as flecainide are not recommended, especially where structural heart disease such as severe LVH or LV systolic dysfunction is evident 12